Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced a public offering of 5 million common shares priced at $20 each, aiming to raise $100 million. The company granted underwriters a 30-day option to buy an additional 750,000 shares. Proceeds will fund development of their drug candidates NXP100, NXP200, and NXP900, as well as general corporate expenses. The offering is expected to close around July 1, 2026, subject to standard conditions.
Ero Copper Corp. held its Annual General and Special Meeting of Shareholders with 82.98% of shares represented. Shareholders re-elected all ten directors, re-appointed KPMG as auditor, and approved amendments to the company's stock option and share u...
Top futures traders have decreased their long positions in Solana (SOL) and Dogecoin (DOGE), while increasing exposure to Bitcoin (BTC) and Ethereum (ETH), indicating a shift in leveraged sentiment. Data shows Dogecoin's USDT-margined long share drop...
Upbit, South Korea's largest crypto exchange, will start trading the decentralized AI compute token Gensyn ($AI) on June 30, 2026, with KRW, BTC, and USDT pairs. This listing comes just over two months after Gensyn's mainnet launch in April, marking ...
A10 Networks (ATEN) is rated a BUY due to its strong earnings performance and expansion in AI-driven security services. The company's solutions have high customer retention due to their mission-critical nature, generating recurring revenues and cross...
In India, the price of Tether's USDT stablecoin surged to a premium of over 8.5% above the official USD/INR exchange rate, reaching 102.88 rupees compared to the official 94.65 rate. This sharp rise from the usual 3-4% premium reflects a sudden short...
